Your shopping cart is currently empty

B I09, an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells., an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells., an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $44 | In Stock | In Stock | |
| 5 mg | $98 | In Stock | In Stock | |
| 10 mg | $163 | In Stock | In Stock | |
| 25 mg | $268 | In Stock | In Stock | |
| 50 mg | $396 | - | In Stock | |
| 100 mg | $562 | - | In Stock |
| Description | B I09, an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells., an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells., an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells. |
| Targets&IC50 | IRE1 Rnase:1230 nM |
| In vitro | B I09 is an IRE-1 RNase inhibitor with an IC50 of 1230 nM[1], effectively inhibiting the splicing of XBP1 mRNA in human WaC3 cells and the expression of XBP-1s in LPS-stimulated B cells[2]. Treatment of CLL cells with B I09 mimics XBP-1 deficiency, including upregulation of IRE-1 expression and compromised BCR signaling. |
| In vivo | B I09 exhibits a half-life of roughly 1.5 hours and achieves its maximum concentration of about 39 μM in mouse plasma serum within 15 minutes post-administration. Upon administration to mice bearing CLL tumors, B I09 effectively halts leukemic progression through apoptosis induction, without inducing systemic toxicity[2]. |
| Molecular Weight | 303.31 |
| Formula | C16H17NO5 |
| Cas No. | 1607803-67-7 |
| Smiles | Oc1ccc2c3CCNCc3c(=O)oc2c1C1OCCCO1 |
| Relative Density. | 1.44 g/cm3 (Predicted) |
| Color | Yellow |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 11 mg/mL (36.27 mM), Sonication is recommended. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.